Literature DB >> 18627775

Tolerability and effects of oral Delta9-tetrahydrocannabinol in older adolescents with marijuana use disorders.

Kevin M Gray1, Carl L Hart, Douglas K Christie, Himanshu P Upadhyaya.   

Abstract

OBJECTIVE: The tolerability and effects of oral Delta9-tetrahydrocannabinol (THC) have been previously investigated in adult marijuana abusers. However, no studies have included adolescent participants. This double-blind laboratory study investigated the tolerability and effects of oral THC in a group of older adolescents with marijuana use disorders.
METHODS: Eight participants (ages 16-21 years), smoking an average of 5.2 days/week and 2.5 "joints"/day, completed this four-session study, during which they received one of four oral THC doses (0, 2.5, 5, 10 mg) each session. Administration of oral THC doses was counterbalanced across participants. During each session, participants completed the Digit-Symbol Substitution Task (DSST) and subjective-effect ratings at baseline and 1, 2, and 3 h after oral THC administration.
RESULTS: Oral THC (5 mg and 10 mg) increased several "positive" subjective-effect ratings (e.g., "Good Drug Effect"), while producing no significant effects on cardiovascular measures, DSST performance, or "negative" subjective-effect ratings.
CONCLUSIONS: These results indicate that oral THC was well tolerated and suggest further study of this medication in adolescent marijuana abusers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627775      PMCID: PMC2567109          DOI: 10.1016/j.pbb.2008.06.011

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  21 in total

1.  Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse.

Authors:  Alan J Budney; Ryan G Vandrey; John R Hughes; Jeff D Thostenson; Zoran Bursac
Journal:  J Subst Abuse Treat       Date:  2008-03-14

2.  Effects of abused drugs on psychomotor performance.

Authors:  W B Pickworth; M S Rohrer; R V Fant
Journal:  Exp Clin Psychopharmacol       Date:  1997-08       Impact factor: 3.157

3.  Effects of acute smoked marijuana on complex cognitive performance.

Authors:  C L Hart; W van Gorp; M Haney; R W Foltin; M W Fischman
Journal:  Neuropsychopharmacology       Date:  2001-11       Impact factor: 7.853

4.  Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure.

Authors:  Carl L Hart; Margaret Haney; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

5.  Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.

Authors:  H Valerie Curran; Catherine Brignell; Sally Fletcher; Paul Middleton; John Henry
Journal:  Psychopharmacology (Berl)       Date:  2002-07-23       Impact factor: 4.530

6.  Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms.

Authors:  Alan J Budney; Ryan G Vandrey; John R Hughes; Brent A Moore; Betsy Bahrenburg
Journal:  Drug Alcohol Depend       Date:  2006-06-12       Impact factor: 4.492

7.  The effects of orally administered delta 9-tetrahydrocannabinol in man on mood and performance measures: a dose-response study.

Authors:  G B Chesher; K D Bird; D M Jackson; A Perrignon; G A Starmer
Journal:  Pharmacol Biochem Behav       Date:  1990-04       Impact factor: 3.533

Review 8.  Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies.

Authors:  Carl L Hart
Journal:  Drug Alcohol Depend       Date:  2005-11-01       Impact factor: 4.492

9.  Abuse potential of dronabinol (Marinol).

Authors:  S R Calhoun; G P Galloway; D E Smith
Journal:  J Psychoactive Drugs       Date:  1998 Apr-Jun

10.  Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence.

Authors:  Jack R Cornelius; Tammy Chung; Christopher Martin; D Scott Wood; Duncan B Clark
Journal:  Addict Behav       Date:  2008-02-11       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.